Clin Psychopharmacol Neurosci.  2019 Feb;17(1):139-142. 10.9758/cpn.2019.17.1.139.

Effectiveness of Pregabalin for Treatment of Burning Mouth Syndrome

Affiliations
  • 1Department of Physical Medicine and Rehabilitation, Division of Algology, Adnan Menderes University Faculty of Medicine, Aydın, Turkey.
  • 2Department of Neurology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey.
  • 3Department of Anesthesiology, Division of Algology, Adnan Menderes University Faculty of Medicine, Aydın, Turkey.
  • 4Department of Neurology, Adnan Menderes University Faculty of Medicine, Aydın, Turkey. aakyol@adu.edu.tr

Abstract

Treatment of burning mouth syndrome (BMS) is challenging because there is no consensus regarding pharmalogical or nonpharmalogical therapies. The use of anticonvulsants is controversial. We present nine patients BMS who respond to pregabalin. They were diagnosed secondary BMS except two. Etiologic regulations were made firstly in patients with secondary BMS but symptoms did not decrease. We preferred pregabalin in all patients and got good results. Furthermore the addition of pregabalin to the treatment of two patients who did not respond adequately to duloxetine provided good results. We are only aware that pregabalin may reduce symptoms as a result of case reports. We believe that the diagnosis of pathologic etiology with appropriate diagnostic tests will result in better outcomes in treatment.

Keyword

Burning mouth syndrome; Anticonvulsants; Pregabalin
Full Text Links
  • CPN
Share
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr